Affiliation:
1. New York University Grossman School of Medicine
2. Danmarks Tekniske Universitet The Novo Nordisk Foundation Center for Biosustainability
3. Cambridge University Hospitals NHS Foundation Trust
Abstract
Vaccines have reduced the transmission and severity of COVID-19 but
there remains a paucity of efficacious treatment for drug resistant
strains and more susceptible individuals. Repurposing existing drugs is
a timely, safe and scientifically robust method for treating pandemics
such as COVID-19. Here, we review the pharmacology and scientific
rationale for repurposing niclosamide, an anti-helminth already in human
use as a treatment for COVID-19. In addition to potent antiviral
activity, niclosamide has shown pleiotropic anti-inflammatory,
antibacterial, bronchodilatory and anticancer effects in numerous
pre-clinical and early clinical studies. The advantages and rationale
for nebulised and intranasal formulations of niclosamide, which target
the site of primary infection in COVID-19, are reviewed. Finally, we
discuss the TACTIC-E clinical trial, an international COVID-19
therapeutic platform trial for the use of licensed and novel therapeutic
agents, which is investigating niclosamide as a promising candidate
against SARS-CoV-2.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献